BioWorld's offices were closed in observance of Presidents Day in the U.S. No issue was published Monday, Feb. 16.

Following through on efforts initiated in November 2025, the U.S. FDA approved drug labeling changes for six menopausal hormone replacement therapies (HRTs) that removes the risk statements related to cardiovascular disease, breast cancer and probable dementia from the boxed warnings.

More than a decade after it was first proposed, the U.S. Precision Medicine Initiative that grew into the NIH’s All of Us dataset has reached its target of collecting genetic and health-related data from 1 million Americans representative of the diversity across the country.

Year-to-date money raised in public, private and other financings of biopharma companies.

Total raised in public, private and other financings of biopharma companies, comparing 2019-2026.

BioWorld's offices will be closed in observance of Presidents Day in the U.S. No issue will be published Monday, Feb. 16.

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Encora, Inmune, Novocure, Serac, Teijin.

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Aardvark, Alkermes, Avadel, Cellprothera, Celyad, Centessa, Eradivir, I-sens, Lifescan, Natus, Nxera, Onconetix, Realbotix, Seres, Therab.

Clinical updates for biopharma and med tech, including data readouts and publications: Annovis, Biovica, Brainscope, Bridgebio, Caredx, Immunesensor, Mesoblast, Surge.

Biopharma and med-tech companies raising money in public or private financings, including: Berlin Heals, Biorestorative, Entirety, Nektar, Neupulse, Neurent, Xilio.